GlassScriptPhysician profile
Bryan D Piotrowski
NPI 1962586289
$9,701.72
in general payments reported to CMS, 2019-2025
29 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,086 · 2020: $1,184 · 2021: $651 · 2022: $726 · 2023: $698 · 2024: $809 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,055.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $5,229.55 | 2019-2023 | Auryon Laser System 100-120 Vac |
| Amgen INC. | $757.93 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $640.81 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $368.73 | 2021-2025 | Verquvo, Capvaxive |
| Novartis Pharmaceuticals Corporation | $313.31 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $294.87 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $278.96 | 2022-2025 | Farxiga, Brilinta |
| Boston Scientific Corporation | $272.00 | 2020-2025 | Watchman Access System, Bodyguardian |
| Sanofi-Aventis U.S. LLC | $211.80 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $189.64 | 2019-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $187.37 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.90 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.24 | 2022 | |
| Vifor Pharma, INC. | $115.54 | 2019-2022 | |
| Pfizer INC. | $97.66 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $86.26 | 2021-2025 | Nexletol |
| Amarin Pharma, INC. | $82.38 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $66.19 | 2019 | |
| Abiomed | $47.71 | 2024-2025 | Impella |
| Medtronic, INC. | $29.85 | 2022-2023 | Mycarelink |
| Apria Healthcare LLC | $25.29 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.97 | 2024 | |
| Edwards Lifesciences Corporation | $20.03 | 2019 | |
| Infobionic, INC | $15.63 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.92 | 2019 | |
| Scpharmaceuticals INC. | $14.20 | 2024 | |
| Janssen Scientific Affairs, LLC | $14.16 | 2024 | Xarelto |
| Bardy Diagnostics, INC. | $13.56 | 2021 | |
| Cvrx, INC. | $10.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Piotrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.